Profile data is unavailable for this security.
About the company
Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company’s developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.
- Revenue in CAD (TTM)39.36k
- Net income in CAD-10.74m
- Incorporated2008
- Employees25.00
- LocationZentek Ltd24 Corporate CtGUELPH N1G 5G5CanadaCAN
- Phone+1 (705) 618-0900
- Fax+1 (705) 618-0900
- Websitehttps://www.zentek.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MustGrow Biologics Corp | 4.71m | -423.96k | 89.92m | 0.00 | -- | 25.23 | -- | 19.08 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -27.64m | 102.55m | 29.00 | -- | 11.15 | -- | -- | -0.3644 | -0.3644 | 0.00 | 0.1175 | 0.00 | -- | -- | -- | -78.58 | -81.99 | -104.96 | -97.25 | -- | -- | -- | -- | -- | -- | 0.1051 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Medicenna Therapeutics Corp | 0.00 | -26.68m | 122.76m | 16.00 | -- | 6.42 | -- | -- | -0.3747 | -0.3747 | 0.00 | 0.2603 | 0.00 | -- | -- | 0.00 | -87.95 | -54.93 | -98.62 | -60.91 | -- | -- | -- | -- | -- | -2.20 | 0.0087 | -- | -- | -- | -153.44 | -- | -- | -- |
| Zentek Ltd | 39.36k | -10.74m | 170.74m | 25.00 | -- | 9.25 | -- | 4,337.90 | -0.1062 | -0.1062 | 0.0004 | 0.1785 | 0.0016 | 0.2262 | 0.1059 | 1,574.40 | -44.08 | -47.65 | -48.37 | -51.12 | -1,038.69 | -- | -27,288.92 | -13,980.33 | 1.63 | -140.86 | 0.0474 | -- | -59.07 | -- | 18.80 | -- | -19.38 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -39.57m | 174.98m | 29.00 | -- | 13.19 | -- | -- | -1.38 | -1.38 | 0.00 | 0.3738 | 0.00 | -- | -- | 0.00 | -162.00 | -127.84 | -261.49 | -935.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
| Cardiol Therapeutics Inc | 0.00 | -36.14m | 180.65m | 17.00 | -- | 14.67 | -- | -- | -0.5318 | -0.5318 | 0.00 | 0.1486 | 0.00 | -- | -- | -- | -119.31 | -58.97 | -158.53 | -68.62 | -- | -- | -- | -158,738.10 | -- | -- | 0.0157 | -- | -- | -- | 9.06 | -- | 36.06 | -- |
| NervGen Pharma Corp | 0.00 | -24.01m | 182.88m | 10.00 | -- | 20.49 | -- | -- | -0.37 | -0.37 | 0.00 | 0.1308 | 0.00 | -- | -- | -- | -123.68 | -121.15 | -332.31 | -180.20 | -- | -- | -- | -- | -- | -22.89 | 0.0139 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Scotia Capital, Inc. (Broker)as of 30 Sep 2024 | 907.03k | 0.89% |
| Desjardins Securities, Inc.as of 30 Sep 2024 | 150.18k | 0.15% |
| CIBC World Markets, Inc.as of 30 Sep 2024 | 126.80k | 0.13% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2024 | 95.42k | 0.09% |
| BMO Asset Management, Inc.as of 30 Sep 2024 | 67.67k | 0.07% |
| TD Waterhouse Canada, Inc.as of 30 Sep 2024 | 27.43k | 0.03% |
| National Bank Financial, Inc.as of 30 Sep 2024 | 26.60k | 0.03% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 20.00k | 0.02% |
| Citadel Securities LLCas of 30 Sep 2024 | 13.49k | 0.01% |
| Warberg Asset Management LLCas of 30 Sep 2024 | 12.00k | 0.01% |
